Pipeline

Internal Programs Early Research Pre-Clinical Phase 1 Phase 2 Phase 3
Etrasimod
GI
ELEVATE UC 52

95%

ELEVATE UC 12

95%

Crohn’s Disease (CD)*

95%

Eosiniphilic Esophagitis (EoE)

73%

Derm
ADVISE – Atopic Dermatitis (AD)

73%

Alopecia Areata (AA)

73%

CR
Controlled Release

58%

Olorinab
GI
CAPTIVATE (Pain with IBS)

73%

Pain with IBD

63%

APD418
CV
Acute HF (AHF)

50%

Partnered / Licensed Programs Early Research Pre-Clinical Phase 1 Phase 2 Phase 3
Ralinepag
UTHR
PAH

95%

Undisclosed Orphan GPCR
CNS

30%

Earlier Stage Internal Platforms: Early Research Pre-Clinical Phase 1 Phase 2 Phase 3
Project Cabrillo
Early Stage Immune & Inflammatory Platform w/ Beacon
Target 1

20%

Target 2

15%

Additional Targets

15%

Arena Neuroscience Platform
Microglial Neuroinflammation Targets
AN143

32%

AN659

32%

Other

20%

Program Indication Phase
Internal Programs
Etrasimod
ELEVATE UC 52 Ph3
ELEVATE UC 12 Ph3
Crohn’s Disease (CD) Ph2/3
Eosiniphilic Esophagitis (EoE) Ph2b Planning
ADVISE – Atopic Dermatitis (AD) Ph2b
Alopecia Areata (AA) Ph2 Planning
Controlled Release (CR) Ph1
Olorinab
CAPTIVATE (Pain with IBS) Ph2b
Pain with IBD Ph2b Planning
APD418
Decompensated HF (DHF) Ph1
Partnered / Licensed Programs
Ralinepag
PAH Ph3
Undisclosed Orphan GPCR
CNS PC
Earlier Stage Internal Platforms
Project Cabrillo
Target 1 Early Research
Target 2 Early Research
Additional Targets Early Research
Arena Neuroscience Platform
AN143 PC
AN659 PC
Other PC

Expanded Access Policy

Last updated as of 04/15/2020